Pcn286 - Incremental Cost-Effectiveness Ratio for the Antineoplastic Drugs Approved and Rejected for the Vital and Essential Drugs List in 2017 in Russia

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.368
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php236 - Quality of Evidence on the Cost-Effectiveness of Drugs Proposed for the Inclusion in the Russian Vital and Essential Drugs List in 2014-2017

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Inclusion of Ipragliflozin Into the Vital and Essential Drugs List: Budget Impact Analysis

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2019English

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014 .

2014English

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 .

2012English

Drug Development Process and Novel Drugs Approved by FDA for 2017 -18

Applied Clinical Research, Clinical Trials and Regulatory Affairs
2018English

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis

PharmacoEconomics - Open
Health PolicyPharmacology
2018English

Clinical Pharmacology of Antineoplastic Drugs

British Journal of Cancer
Cancer ResearchOncology
1979English

Repurposing FDA-approved Drugs for Anti-Aging Therapies

Biogerontology
AgingGerontologyGeriatrics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy